Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -4165.92% is 22848% below its 4-year average of -18.15%, near the low end of its 4-year range (-4165.92%–103.99%).
6913.18% below its 12-month average of 61.14%.
Annual fiscal-year return on equity; no daily interpolation. Historical series through 2025-12-31.
RETURN ON EQUITY (ROE)
-4165.92%
RETURN ON EQUITY (ROE) AVG TTM
61.14%
RETURN ON EQUITY (ROE) AVG 3Y
-23.12%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-6913.18%
CURRENT VS 3Y AVG
-17918.69%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-41.20%
median of 733 covered companies
CURRENT VS SECTOR MEDIAN
-10011.46%
vs the sector median at left
Liminatus Pharma, Inc. Class A Common Stock
Market Cap
$5.00M
Return on Equity (ROE)
-4165.92%
TTM Avg
61.14%
3Y Avg
-23.12%
5Y Avg
N/A
Market Cap
$5.03M
Return on Equity (ROE)
-248.66%
TTM Avg
-110.63%
3Y Avg
-33.84%
5Y Avg
-33.84%
Market Cap
$5.02M
Return on Equity (ROE)
-351.30%
TTM Avg
-321.98%
3Y Avg
-228.03%
5Y Avg
-177.46%
Market Cap
$5.02M
Return on Equity (ROE)
-163.18%
TTM Avg
-235.11%
3Y Avg
-195.15%
5Y Avg
-161.13%
Market Cap
$4.83M
Return on Equity (ROE)
-40.76%
TTM Avg
-51.09%
3Y Avg
-48.10%
5Y Avg
-52.04%
Market Cap
$5.21M
Return on Equity (ROE)
N/A
TTM Avg
383.38%
3Y Avg
131.31%
5Y Avg
101.98%
Market Cap
$5.22M
Return on Equity (ROE)
-156.94%
TTM Avg
-121.17%
3Y Avg
-95.34%
5Y Avg
-84.55%
Market Cap
$5.20M
Return on Equity (ROE)
-42.05%
TTM Avg
-32.76%
3Y Avg
-25.11%
5Y Avg
-45.26%
Market Cap
$5.24M
Return on Equity (ROE)
-225.57%
TTM Avg
-289.16%
3Y Avg
-245.03%
5Y Avg
-192.04%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | $5.00M | -4165.92% | 61.14% | -23.12% | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.03M | -248.66% | -110.63% | -33.84% | -33.84% |
| Imunon, Inc. (IMNN)vs › | $5.02M | -351.30% | -321.98% | -228.03% | -177.46% |
| Lexaria Bioscience Corp. (LEXX)vs › | $5.02M | -163.18% | -235.11% | -195.15% | -161.13% |
| Xenetic Biosciences, Inc. (XBIO)vs › | $4.83M | -40.76% | -51.09% | -48.10% | -52.04% |
| Lunai Bioworks Inc. (LNAI)vs › | $5.21M | N/A | 383.38% | 131.31% | 101.98% |
| Pulmatrix, Inc. (PULM)vs › | $5.22M | -156.94% | -121.17% | -95.34% | -84.55% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.20M | -42.05% | -32.76% | -25.11% | -45.26% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.24M | -225.57% | -289.16% | -245.03% | -192.04% |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.71M | -54.15% | 0.37% | -1.09% | -10.37% |
ROE
-4165.9%
ROA
-367.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 103.99% |
| 2024-12-31 | 18.30% |
| 2023-12-31 | 11.47% |
| 2022-12-31 | -226.24% |
| 2021-12-31 | 1.71% |
